Lundbeck/Takeda’s Brintellix Passes Muster In Three Of Four Pivotal Trials
Executive Summary
The multimodal antidepressant Brintellix (vortioxetine), now pending at FDA, has an intriguing mechanism of action that hits a number of receptors, which in theory could translate into better effects. But in studies presented at the APA meeting, its efficacy and safety looked on par with other antidepressants.